Maxwell Biosciences Appoints Kent Kirshenbaum, Ph.D. as Chief Scientific Officer and Sheetal Vali, Ph.D. as Director of Drug Development

Mar 3

The week of February 16th, Maxwell Biosciences announced Kent Kirshenbaum, Ph.D. as Chief Scientific Officer and Sheetal Vali, Ph.D. as Director of Drug Development and entered into license with NYU for patents that originated as a result of Kirshenbaum’s research discoveries.

Full coverage

2/16/2021 Business Wire: New York University Professor of Chemistry Dr. Kent Kirshenbaum Named Chief Scientific Officer at Maxwell Biosciences

2/16/2021 Business Wire: Maxwell Biosciences Appoints Sheetal Vali, Ph.D. as Director of Drug Development

2/16/2021 First Word Pharma: Maxwell Biosciences Appoints Sheetal Vali as Director of Drug Development

2/16/2021 BioSpace: Maxwell Biosciences Appoints Sheetal Vali, Ph.D. as Director of Drug Development

2/16/2021 BioSpace: New York University Professor of Chemistry Dr. Kent Kirshenbaum Named Chief Scientific Officer at Maxwell Biosciences

2/16/2021 CityBizList: NY University Professor of Chemistry Dr. Kent Kirshenbaum Named Chief Scientific Officer at Maxwell Biosciences

2/16/2021 Digital Journal: New York University Professor of Chemistry Dr. Kent Kirshenbaum Named Chief Scientific Officer at Maxwell Biosciences

2/16/2021 The Pharmaceutical Marketing Group: Maxwell Biosciences Appoints Sheetal Vali, Ph.D. as Director of Drug Development

2/17/2021 Pharmaceutical Daily: Maxwell Biosciences Appoints Sheetal Vali, Ph.D. as Director of Drug Development

2/17/2021 BioWorld: Appointments and advancements for Feb. 17, 2021

2/19/2021 EndPoints: EndPoints News: Weekly BioPharma Job Report